Immune Pharmaceuticals Stock Piotroski F Score

This module uses fundamental data of Immune Pharmaceuticals to approximate its Piotroski F score. Immune Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Immune Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Immune Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
  
At this time, it appears that Immune Pharmaceuticals' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Unavailable
Current Return On Assets

N/A

Focus
Change in Return on Assets

N/A

Focus
Cash Flow Return on Assets

N/A

Focus
Current Quality of Earnings (accrual)

N/A

Focus
Asset Turnover Growth

N/A

Focus
Current Ratio Change

N/A

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

N/A

Focus
Change in Gross Margin

N/A

Focus

Immune Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Immune Pharmaceuticals is to make sure Immune is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Immune Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Immune Pharmaceuticals' financial numbers are properly reported.

About Immune Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Immune OTC Stock

If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stocks Directory
Find actively traded stocks across global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios